17,261 trials
Dental Caries
Primary: Caries Activity and Progression Assessment Using LASER Fluorescence Readings by Diagnodent® Device. — 18.6; 1.1 units on a scale
Cancer Diagnosis · Diagnostic Techniques and Procedures · Diagnostic Imaging
Primary: Absolute Accuracy of SUV Max of PET/CT vs PET/MRI — 1.78; 1.08; 0.54; 0.51 ratio
Cutaneous T Cell Lymphoma
Primary: Number of Participants Reported Overall Response (Complete and Partial) of Target Treated Lesions Based on Modified Composite Assessment of Index Lesion Severity…
Adenocarcinoma
Primary: Overall Survival — 15.7; 9.0 months — p=0.0024
Hidradenitis Suppurativa (HS)
Primary: Number of Patients With Hidradenitis Suppurativa Clinical Response (HiSCR) Determined at Week 16 — 16; 12; 17; 12 Participants
Idiopathic Pulmonary Fibrosis
Primary: Number of Participants With Adverse Events — 0; 0; 2; 3 Participants
Non-small Cell Lung Cancer
Primary: Phase Ib: Frequency of Dose Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants
Advanced Lymphoma · Advanced Malignant Solid Neoplasm · Hematopoietic and Lymphoid Cell Neoplasm
Primary: Overall Response Rate (ORR) — 35.7 percentage of participants
Type 1 Diabetes Mellitus
Primary: Insulin Maximum Observed Concentration (Cmax) — 28.5; 102; 101; 133 μU/mL
Mesothelioma · Pleural Mesothelioma
Primary: Overall Survival (OS) — 20.4 months
Stage II Lymphoepithelioma of the Nasopharynx · Stage II Squamous Cell Carcinoma of the Nasopharynx · Stage III Lymphoepithelioma of the Nasopharynx
Primary: Number of Participants With Progression-free Survival (PFS) at 2 Years After Chemo-radiotherapy — 18; 4 Participants
Gastric Adenocarcinoma · Esophageal Cancer · Hepatocellular Carcinoma
Primary: Percentage of Participants Experiencing Any Treatment Emergent Adverse Events and Serious Treatment Emergent Adverse Events — 100.0; 100.0; 100.0; 99.8 Percentage of…
Blood Transfusion Complications
Primary: Biomarkers Associated With Transfusion-Related Acute Lung Injury and Transfusion Associated Circulatory Overload. — 101; 105; 12; 15 units on a scale (pg/ml)
Recurrent Renal Cell Carcinoma · Stage III Renal Cell Cancer AJCC v7 · Stage IV Renal Cell Cancer AJCC v7
Primary: Objective Response for BAY 43-9006 in Combination With Gemcitabine and Capecitabine Evaluated by the Response Evaluation Criteria in Solid Tumors (RECIST) — 5 Participants
Head and Neck Cancer
Primary: Incidence of Grade ≥3 Oral Mucositis Determined by Clinical Examination and Assessed by Central Review According to the Common Terminology Criteria of Adverse Events…